Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Convertible Debt (2016 - 2020)

Amicus Therapeutics filings provide 5 years of Convertible Debt readings, the most recent being $2.2 million for Q2 2020.

  • On a quarterly basis, Convertible Debt rose 6.43% to $2.2 million in Q2 2020 year-over-year; TTM through Jun 2020 was $2.2 million, a 6.43% increase, with the full-year FY2019 number at $2.1 million, down 98.78% from a year prior.
  • Convertible Debt hit $2.2 million in Q2 2020 for Amicus Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $175.0 million in Q4 2018 to a low of $2.1 million in Q2 2019.
  • Median Convertible Debt over the past 5 years was $156.9 million (2017), compared with a mean of $100.8 million.
  • Biggest five-year swings in Convertible Debt: grew 6.6% in 2018 and later crashed 98.78% in 2019.
  • Amicus Therapeutics' Convertible Debt stood at $154.5 million in 2016, then grew by 6.28% to $164.2 million in 2017, then increased by 6.6% to $175.0 million in 2018, then plummeted by 98.78% to $2.1 million in 2019, then increased by 3.38% to $2.2 million in 2020.
  • The last three reported values for Convertible Debt were $2.2 million (Q2 2020), $2.2 million (Q1 2020), and $2.1 million (Q4 2019) per Business Quant data.